Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.84+0.02 (+2.78%)
Close on Nov 18, 2026Market cap $212.06MP/E –Yield –
Lineage Cell Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Lineage Cell Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $13.08M, up 19.9% year over year. For fiscal 2025 it was $14.56M, up 53.2% from the year before. Over ten years it grew 7.5% a year on average. The highest annual figure on record is $14.70M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.56M | +53.2% |
| FY2024 | Dec 31, 2024 | $9.50M | +6.2% |
| FY2023 | Dec 31, 2023 | $8.95M | -39.2% |
| FY2022 | Dec 31, 2022 | $14.70M | +238.7% |
| FY2021 | Dec 31, 2021 | $4.34M | +137.7% |
| FY2020 | Dec 31, 2020 | $1.83M | -48.1% |
| FY2019 | Dec 31, 2019 | $3.52M | -29.5% |
| FY2018 | Dec 31, 2018 | $4.99M | +44.2% |
| FY2017 | Dec 31, 2017 | $3.46M | -41.6% |
| FY2016 | Dec 31, 2016 | $5.92M | -15.8% |
| FY2015 | Dec 31, 2015 | $7.04M | +34.2% |
| FY2014 | Dec 31, 2014 | $5.24M | +18.3% |
| FY2013 | Dec 31, 2013 | $4.43M | +13.2% |
| FY2012 | Dec 31, 2012 | $3.92M | -11.7% |
| FY2011 | Dec 31, 2011 | $4.43M | +19.6% |
| FY2010 | Dec 31, 2010 | $3.71M | +92.6% |
| FY2009 | Dec 31, 2009 | $1.93M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.07M | -61.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.73M | +14.8% |
| Q4 FY2025 | Dec 31, 2025 | $6.61M | +130.4% |
| Q3 FY2025 | Sep 30, 2025 | $3.68M | -2.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.77M | +96.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.50M | +4.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.87M | +37.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.78M | +203.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.41M | -56.3% |
| Q1 FY2024 | Mar 31, 2024 | $1.44M | -39.5% |
| Q4 FY2023 | Dec 31, 2023 | $2.09M | +9.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.25M | -58.4% |
| Q2 FY2023 | Jun 30, 2023 | $3.23M | -29.2% |
| Q1 FY2023 | Mar 31, 2023 | $2.39M | -54.4% |
| Q4 FY2022 | Dec 31, 2022 | $1.92M | +64.0% |
| Q3 FY2022 | Sep 30, 2022 | $3.00M | +32.1% |
| Q2 FY2022 | Jun 30, 2022 | $4.55M | +789.3% |
| Q1 FY2022 | Mar 31, 2022 | $5.24M | +1239.4% |
| Q4 FY2021 | Dec 31, 2021 | $1.17M | +229.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.27M | +297.5% |
| Q2 FY2021 | Jun 30, 2021 | $512.00K | +32.6% |
| Q1 FY2021 | Mar 31, 2021 | $391.00K | -23.9% |
| Q4 FY2020 | Dec 31, 2020 | $355.00K | -71.4% |
| Q3 FY2020 | Sep 30, 2020 | $571.00K | +0.7% |
| Q2 FY2020 | Jun 30, 2020 | $386.00K | -50.4% |
| Q1 FY2020 | Mar 31, 2020 | $514.00K | -44.6% |
| Q4 FY2019 | Dec 31, 2019 | $1.24M | +63.7% |
| Q3 FY2019 | Sep 30, 2019 | $567.00K | -42.3% |
| Q2 FY2019 | Jun 30, 2019 | $779.00K | -69.4% |
| Q1 FY2019 | Mar 31, 2019 | $928.00K | +32.4% |
| Q4 FY2018 | Dec 31, 2018 | $758.00K | -19.8% |
| Q3 FY2018 | Sep 30, 2018 | $982.00K | -40.0% |
| Q2 FY2018 | Jun 30, 2018 | $2.55M | +577.4% |
| Q1 FY2018 | Mar 31, 2018 | $701.00K | +110.5% |
| Q4 FY2017 | Dec 31, 2017 | $945.00K | -14.3% |
| Q3 FY2017 | Sep 30, 2017 | $1.64M | +13.5% |
| Q2 FY2017 | Jun 30, 2017 | $376.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $333.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $1.10M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.44M | – |
See a number that looks wrong?